Global Pharma & Healthcare Weekly Newsletter
Wegovy MASH Approval, Singapore HSA Actions, India Q1 Results
Coverage: August 11–17, 2025
Introduction
The week delivered two major U.S. approvals (including Wegovy for MASH and the first immunotherapy for recurrent respiratory papillomatosis), notable Indian corporate disclosures, vigorous enforcement actions in Singapore, and several UAE public‑health initiatives.
Major News from Pharma and Healthcare
India — Regulators & Companies
- CDSCO posts updated COVID‑19 vaccine list (Aug 11): India’s national regulator refreshed its public register of COVID‑19 vaccines approved for use, helping clinicians and the public see the current portfolio at a glance.
- Lupin signs ranibizumab biosimilar deal with Sandoz (Aug 12): Lupin will manufacture and handle filings while Sandoz commercializes in designated markets, expanding access to a key ophthalmology biologic.
- Lupin launches Glucagon in the U.S. (Aug 11): The emergency kit for severe hypoglycemia enters the U.S. market as a bioequivalent alternative to the reference product.
- Zydus Lifesciences Q1 FY26 results (Aug 12): The company reported steady year‑on‑year revenue growth and highlighted performance across India and the U.S. generics business.
- Glenmark Pharmaceuticals Q1 FY26 results (Aug 14): Glenmark published its first‑quarter financials via stock‑exchange filing, noting flat top‑line growth and an adjusted PAT update.
Singapore — Enforcement & Public Health
- HSA partners nightlife sector to deter vaping (Aug 16): The authority launched a joint effort with venue operators, adding signage and QR reporting tools to curb illicit e‑vaporizer use.
- HSA details 70 cases involving etomidate‑laced vapes (Aug 14): Officials summarized investigations, prosecutions, and upcoming control measures for adulterated e‑vaporizer products.
Middle East — UAE health programs & safety actions
- MOHAP marks World Organ Donation Day (Aug 13): Awareness activities and policy messaging reinforced organ donation efforts nationally.
- MOHAP expands Newborn Screening Programme (Aug 12): Collaboration with private hospitals aims to catch metabolic and genetic disorders earlier.
- MOHAP wraps hotspots/heat‑exhaustion awareness phase (Aug 11): Seasonal prevention messaging continued across high‑risk settings.
- Dubai Health Authority recall circular (Aug 11): DHA issued an urgent market recall covering products from a specific manufacturer, underscoring vigilance in the emirate.
- Julphar corporate updates (Aug 13): Julphar released an anniversary community‑health initiative and disclosed board‑meeting results on ADX.
- Cleveland Clinic Abu Dhabi case milestone (Aug 13): The hospital highlighted a complex double‑organ transplant outcome, signaling growing specialty‑care capability in the region.
United States — Approvals & Research
- FDA approves Wegovy (semaglutide) for MASH with fibrosis (Aug 15): This is a pivotal addition for patients with moderate‑to‑advanced fibrosis due to MASH.
- FDA approves first immunotherapy for RRP (Aug 14): Papzimeos (zopapogene imadenovec‑drba) becomes the first therapy of its kind for recurrent respiratory papillomatosis.
- NIH reports preclinical gene‑editing advance for late‑onset Tay‑Sachs (Aug 15): NIH‑backed researchers outlined a potential path for treating this lysosomal storage disorder.
- Merck (MSD) corporate update (Aug 12): Merck issued an investor‑facing note on integrating the Prometheus Analytics acquisition into its R&D and data stack.
- Context: opioid labeling updates & gene‑therapy safety (late July–early Aug): Outside this week’s exact window, FDA recently required class‑wide opioid labeling changes (July 31) and issued multiple Elevidys safety communications (late June–July); these ongoing actions remain relevant for prescribing and gene‑therapy oversight.
Regional Summary Tables
India — Official Releases & Filings (Aug 11–14)
| Issuer | Headline / Topic | Notes |
|---|---|---|
| CDSCO | COVID‑19 vaccines approved in India (as on 11.08.2025) | Latest consolidated vaccine list |
| Lupin | Licensing deal for ranibizumab biosimilar with Sandoz | Lupin manufactures; Sandoz commercializes in defined markets |
| Lupin | Launch of Glucagon for Injection in the U.S. | Emergency kit for severe hypoglycemia |
| Zydus Lifesciences | Q1 FY26 results | Revenue up ~6% YoY; stable EBITDA margin |
| Glenmark Pharma | Q1 FY26 results | Consolidated revenue ~₹32,644 mn; adjusted PAT margin noted |
Glenmark Pharma Market share
Singapore — HSA Announcements (Aug 14–16)
| Issuer | Headline / Topic | Impact |
|---|---|---|
| HSA | Collaboration with Singapore Nightlife Business Association to curb vaping | High (venue‑level deterrence) |
| HSA (with MOH context) | Update on 70 cases linked to etomidate‑laced e‑vaporisers | Critical (public‑safety risk) |
Middle East — UAE Health System Updates (Aug 11–13)
| Issuer | Headline / Topic |
|---|---|
| MOHAP (UAE) | World Organ Donation Day activities |
| MOHAP (UAE) | Private‑hospital collaboration on National Newborn Screening Programme |
| MOHAP (UAE) | Seasonal heat‑exhaustion/disease‑prevention campaign progress |
| Dubai Health Authority | Urgent recall of all medical products by Ameya FZC |
| Julphar | 50th anniversary cancer‑support initiative |
| Julphar → ADX | Board‑meeting results |
| Cleveland Clinic Abu Dhabi | Complex double‑organ transplant success story |
United States — FDA / NIH / Corporate (Aug 12–15)
| Issuer | Headline / Topic | Significance |
|---|---|---|
| FDA | Wegovy approved for treatment of MASH with fibrosis | Breakthrough for liver disease |
| FDA | First immunotherapy for RRP approved (Papzimeos) | First‑in‑class for RRP |
| NIH (NINDS) | Preclinical gene‑editing advance for late‑onset Tay‑Sachs | Rare‑disease pipeline signal |
| Merck (MSD) | Update on Prometheus Analytics integration | Corporate strategy |
Master Pharma and Healthcare Weekly News
| Issuer | Topic / Category | Snapshot |
|---|---|---|
| CDSCO,India | COVID‑19 vaccine list refresh | Updated official inventory of authorized vaccines |
| Lupin,India/US | Glucagon U.S. launch | Adds a generic emergency kit option for severe hypoglycemia |
| MOHAP,UAE | Heat‑exhaustion campaign | Seasonal prevention milestone |
| DHA,Dubai (UAE) | Urgent product recall circular | Market‑safety action |
| Lupin, India | Ranibizumab biosimilar licensing with Sandoz | Access‑expansion in ophthalmology |
| Zydus, India | Q1 FY26 results | Financial disclosure |
| MOHAP, UAE | Organ donation awareness | Public‑health initiative |
| Julphar, UAE | Corporate anniversary initiative + ADX disclosure | Investor & CSR updates |
| Cleveland Clinic Abu Dhabi | Complex transplant outcome | Specialty‑care milestone |
| Glenmark, India | Q1 FY26 results | Financial disclosure |
| FDA, US | Papzimeos approved for RRP | First immunotherapy for this condition |
| FDA | Wegovy approved for MASH | Therapeutic advance for liver disease |
| NIH, US | Gene‑editing progress for late‑onset Tay‑Sachs | Preclinical research signal |
| HSA, Singapore | Nightlife anti‑vaping collaboration | Venue‑level enforcement drive |
FAQs on Pharma and Healthcare Official News
Q1. Why is Wegovy’s MASH indication a big deal?
Because patients with moderate‑to‑advanced fibrosis due to MASH have had few options; the approval puts a widely known GLP‑1 on‑label for a serious liver disease, potentially shifting standards of care and payer coverage.
Q2. What does Papzimeos’ approval change for RRP?
RRP often forces patients into repeated surgeries to clear papillomas. An approved immunotherapy creates a systemic treatment path that could reduce procedures and improve long‑term control.
Q3. How should venues in Singapore react to HSA’s anti‑vaping push?
Post the official signage, enable QR reporting as directed, train staff on spot‑checks, and document incidents so evidence flows quickly to HSA.
Q4. What’s the practical impact of Dubai’s urgent recall notice?
Pharmacies and clinics should quarantine any affected stock immediately, notify suppliers, and follow DHA return or disposal instructions to avoid patient exposure.
Q5. For India, what do the week’s company filings signal?
Earnings prints from Zydus and Glenmark point to steady—if uneven—growth across domestic and U.S. markets, while Lupin’s ranibizumab deal and U.S. Glucagon launch illustrate ongoing moves into complex biologics and hospital‑critical injectables.
Venkat